scPharmaceuticals Inc.
SCPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $36 | $14 | $0 | $0 |
| % Growth | 167.3% | – | – | – |
| Cost of Goods Sold | $11 | $4 | $0 | $0 |
| Gross Profit | $25 | $10 | -$0 | -$0 |
| % Margin | 68.7% | 72% | – | – |
| R&D Expenses | $12 | $12 | $16 | $16 |
| G&A Expenses | $0 | $53 | $21 | $10 |
| SG&A Expenses | $78 | $53 | $21 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $90 | $65 | $36 | $26 |
| Operating Income | -$65 | -$55 | -$36 | -$26 |
| % Margin | -178.3% | -407.5% | – | – |
| Other Income/Exp. Net | -$20 | $1 | -$1 | -$2 |
| Pre-Tax Income | -$85 | -$55 | -$37 | -$28 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$85 | -$55 | -$37 | -$28 |
| % Margin | -234.4% | -403.2% | – | – |
| EPS | -1.91 | -1.42 | -1.3 | -1.02 |
| % Growth | -34.5% | -9.2% | -27.5% | – |
| EPS Diluted | -1.91 | -1.42 | -1.3 | -1.02 |
| Weighted Avg Shares Out | 45 | 39 | 28 | 27 |
| Weighted Avg Shares Out Dil | 45 | 39 | 28 | 27 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $5 | $1 | $0 |
| Interest Expense | $8 | $8 | $3 | $3 |
| Depreciation & Amortization | $0 | $1 | $0 | $0 |
| EBITDA | -$77 | -$46 | -$33 | -$25 |
| % Margin | -213.1% | -338.9% | – | – |